Compare TKNO & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TKNO | EVO |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.7M | 568.6M |
| IPO Year | 2021 | 2007 |
| Metric | TKNO | EVO |
|---|---|---|
| Price | $7.01 | $1.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $9.67 | $4.23 |
| AVG Volume (30 Days) | ★ 564.9K | 84.4K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,520,000.00 | N/A |
| Revenue This Year | $13.54 | N/A |
| Revenue Next Year | $14.51 | $20.47 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.35 | N/A |
| 52 Week Low | $1.91 | $1.33 |
| 52 Week High | $9.48 | $4.19 |
| Indicator | TKNO | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 46.18 | 49.89 |
| Support Level | $6.33 | $1.50 |
| Resistance Level | $7.66 | $1.97 |
| Average True Range (ATR) | 0.59 | 0.05 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 53.90 | 86.79 |
Alpha Teknova Inc is a producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics. Its offer two primary product categories: Lab Essentials and Clinical Solutions. It derives key revenue from the United States. The company offers three primary product types: (i) pre-poured media plates for cell growth and cloning; (ii) liquid microbial culture media and supplements for cellular expansion; and (iii) molecular biology reagents for sample manipulation, resuspension, and purification.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.